Annual Working Capital
$5.58 M
-$4.46 M-44.45%
31 December 2023
Summary:
Monopar Therapeutics annual working capital is currently $5.58 million, with the most recent change of -$4.46 million (-44.45%) on 31 December 2023. During the last 3 years, it has fallen by -$10.05 million (-64.32%). MNPR annual working capital is now -70.57% below its all-time high of $18.94 million, reached on 31 December 2021.MNPR Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Working Capital
$4.95 M
-$1.14 M-18.78%
30 September 2024
Summary:
Monopar Therapeutics quarterly working capital is currently $4.95 million, with the most recent change of -$1.14 million (-18.78%) on 30 September 2024. Over the past year, it has dropped by -$1.64 million (-24.89%). MNPR quarterly working capital is now -80.24% below its all-time high of $25.03 million, reached on 31 March 2021.MNPR Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
MNPR Working Capital Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -44.5% | -24.9% |
| 3 y3 years | -64.3% | -76.7% |
| 5 y5 years | -18.6% | +7.0% |
MNPR Working Capital High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -70.6% | at low | -76.7% | at low |
| 5 y | 5 years | -70.6% | at low | -80.2% | +7.0% |
| alltime | all time | -70.6% | +174.5% | -80.2% | +7.0% |
Monopar Therapeutics Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $4.95 M(-18.8%) |
| June 2024 | - | $6.09 M(-18.5%) |
| Mar 2024 | - | $7.48 M(+34.1%) |
| Dec 2023 | $5.58 M(-44.5%) | $5.58 M(-15.4%) |
| Sept 2023 | - | $6.59 M(-15.6%) |
| June 2023 | - | $7.80 M(-12.3%) |
| Mar 2023 | - | $8.90 M(-11.4%) |
| Dec 2022 | $10.04 M(-47.0%) | $10.04 M(-19.4%) |
| Sept 2022 | - | $12.46 M(-13.9%) |
| June 2022 | - | $14.47 M(-14.6%) |
| Mar 2022 | - | $16.94 M(-10.6%) |
| Dec 2021 | $18.94 M | $18.94 M(-10.7%) |
| Sept 2021 | - | $21.21 M(-8.9%) |
| June 2021 | - | $23.28 M(-7.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2021 | - | $25.03 M(+60.2%) |
| Dec 2020 | $15.62 M(+24.9%) | $15.62 M(-10.6%) |
| Sept 2020 | - | $17.48 M(+43.8%) |
| June 2020 | - | $12.16 M(-1.0%) |
| Mar 2020 | - | $12.27 M(-1.9%) |
| Dec 2019 | $12.51 M(+82.5%) | $12.51 M(+170.4%) |
| Sept 2019 | - | $4.62 M(-9.8%) |
| June 2019 | - | $5.13 M(-11.2%) |
| Mar 2019 | - | $5.77 M(-15.7%) |
| Dec 2018 | $6.85 M(-22.3%) | $6.85 M(-9.5%) |
| Sept 2018 | - | $7.58 M(+3.4%) |
| June 2018 | - | $7.32 M(-9.1%) |
| Mar 2018 | - | $8.06 M(-8.6%) |
| Dec 2017 | $8.82 M(+334.3%) | $8.82 M |
| Dec 2016 | $2.03 M | - |
FAQ
- What is Monopar Therapeutics annual working capital?
- What is the all time high annual working capital for Monopar Therapeutics?
- What is Monopar Therapeutics annual working capital year-on-year change?
- What is Monopar Therapeutics quarterly working capital?
- What is the all time high quarterly working capital for Monopar Therapeutics?
- What is Monopar Therapeutics quarterly working capital year-on-year change?
What is Monopar Therapeutics annual working capital?
The current annual working capital of MNPR is $5.58 M
What is the all time high annual working capital for Monopar Therapeutics?
Monopar Therapeutics all-time high annual working capital is $18.94 M
What is Monopar Therapeutics annual working capital year-on-year change?
Over the past year, MNPR annual working capital has changed by -$4.46 M (-44.45%)
What is Monopar Therapeutics quarterly working capital?
The current quarterly working capital of MNPR is $4.95 M
What is the all time high quarterly working capital for Monopar Therapeutics?
Monopar Therapeutics all-time high quarterly working capital is $25.03 M
What is Monopar Therapeutics quarterly working capital year-on-year change?
Over the past year, MNPR quarterly working capital has changed by -$1.64 M (-24.89%)